cyproterone and Laryngeal-Neoplasms

First clinical experiences with the anti-androgenic drug cyproterone-acetate in treatment of pachydermia laryngis are reported in eleven male and female patients. This endocrine therapy led to complete healing in four and to marked improvement in six patients. One did not respond. Evaluation of the endocrine state of these patients showed imbalance in the androgen/estrogen equilibrium. As the larynx constitutes a secondary sex characteristic and an endocrine target organ, the significance of endocrine factors for pathogenesis and therapy of epithelial changes on the vocal cords is discussed.

Topics: Androgen Antagonists; Cyproterone; Female; Hirsutism; Humans; Laryngeal Diseases; Laryngeal Edema; Laryngeal Neoplasms; Leukoplakia, Oral; Male; Middle Aged

Case-report about a 56 year old white female patient with pachydermia laryngis and hirsutism, successfully treated with cyproterone-acetate, a testosterone antagonist. The significance of androgenic hormones for the development of epithelial changes in the female larynx is emphasized. The administration of antiandrogenic substances as a new therapeutic measure is discussed.

Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Cyproterone; Estrogens; Female; Hirsutism; Humans; Laryngeal Neoplasms; Middle Aged; Precancerous Conditions; Testosterone; Vocal Cords